LivRelief Varicose Veins Cream in the Treatment of Varicose Veins
Primary Purpose
Varicose Veins
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Natural Health Product: LivRelief Varicose Veins Cream
Sponsored by
About this trial
This is an interventional treatment trial for Varicose Veins
Eligibility Criteria
Inclusion Criteria:
- At least 19 years of age.
- Presence of lower limb varicose veins.
Exclusion Criteria:
- Allergy to witch-hazel or any allergies in the cream.
- Intent to undergo surgical treatment varicose veins within the next six weeks.
- Pregnant or breastfeeding or planning to be pregnant.
- Any Dementia or Major Cognitive dysfunction that would preclude the individual's ability to provide informed consent or complete the Case Report Form.
- Any unstable medical condition (including but not limited to cardiovascular, cardiac/hypertension disease, moderate to severe kidney disease, and moderate to severe liver disease)
- Any medical condition that would preclude the participant's or a caregiver's ability to administer the product on a daily basis for the time period required to complete the study.
- An active ulcer at the site of product application (as evaluated during CEAP screening).
Sites / Locations
- The Mayer Institute
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
LivRelief Varicose Veins Cream
Arm Description
Intervention: All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use.
Outcomes
Primary Outcome Measures
Recruitment feasibility
Recruitment of at least 70% of all eligible participants
Data Collection
Collection of at least 70% of scheduled data
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03653793
Brief Title
LivRelief Varicose Veins Cream in the Treatment of Varicose Veins
Official Title
LivRelief Varicose Veins Cream in the Treatment of Chronic Venous Insufficiency of the Lower Limbs: A 6-week Single Arm Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
May 23, 2017 (Actual)
Primary Completion Date
August 28, 2017 (Actual)
Study Completion Date
August 28, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Delivra, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Phase IV interventional design where all participants used the test product as per package instructions for 6-weeks. Baseline observations were compared to those collected after 6-weeks of treatment.
Detailed Description
The use of the marketed natural product, LivRelief Varicose Veins Cream, was observed in 32 patients with lower limb varicose veins. Participants were recruited from the patient population at The Mayer Institute in Hamilton Ontario, Canada. Patients that agreed to participate in the study and met the eligibility criteria were provided with a 6-week supply of the cream to use at home as directed on the product packaging. The following study measures were performed at the clinic prior to the first use of the cream, then again at the clinic after 6 weeks of use: CEAP (Clinical, Etiological, Anatomical, Pathophysiological) classification and VCSS (Venous Clinical Severity score). These are assessments performed by the doctor or nurse to determine the severity of their varicose veins and CVI (chronic venous insufficiency), measurements taken of the circumference of their legs to measure swelling of the legs, photographs of the varicose veins, a quality of life enjoyment and satisfaction questionnaire (QLES-Q-SF) completed by the subjects to describe their satisfaction with various aspects of their life over the last week and documentation of any reactions to the treatment. The cream was applied to their varicose veins twice a day for 6 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Varicose Veins
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This was a single arm pilot study to determine the feasibility of conducting an appropriately sized RCT within the same population using the same clinical outcome measures.
Eligible adult patients of the clinic with varicose veins were asked to use the cream as directed on the packaging for 6-weeks and the post-treatment measures were compared to baseline data. This study also provided SDs of the sample for comparison to the study population.
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LivRelief Varicose Veins Cream
Arm Type
Experimental
Arm Description
Intervention:
All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use.
Intervention Type
Other
Intervention Name(s)
Natural Health Product: LivRelief Varicose Veins Cream
Other Intervention Name(s)
Natural Product Number (NPN) 80029349
Intervention Description
This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
Primary Outcome Measure Information:
Title
Recruitment feasibility
Description
Recruitment of at least 70% of all eligible participants
Time Frame
study duration:~4 weeks
Title
Data Collection
Description
Collection of at least 70% of scheduled data
Time Frame
study duration: ~6 to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
At least 19 years of age.
Presence of lower limb varicose veins.
Exclusion Criteria:
Allergy to witch-hazel or any allergies in the cream.
Intent to undergo surgical treatment varicose veins within the next six weeks.
Pregnant or breastfeeding or planning to be pregnant.
Any Dementia or Major Cognitive dysfunction that would preclude the individual's ability to provide informed consent or complete the Case Report Form.
Any unstable medical condition (including but not limited to cardiovascular, cardiac/hypertension disease, moderate to severe kidney disease, and moderate to severe liver disease)
Any medical condition that would preclude the participant's or a caregiver's ability to administer the product on a daily basis for the time period required to complete the study.
An active ulcer at the site of product application (as evaluated during CEAP screening).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Perry V Mayer, MD
Organizational Affiliation
The Mayer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Mayer Institute
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8R 2R3
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30596677
Citation
Dwyer HC, Baranowski DC, Mayer PV, Gabriele S. LivRelief varicose veins cream in the treatment of chronic venous insufficiency of the lower limbs: A 6-week single arm pilot study. PLoS One. 2018 Dec 31;13(12):e0208954. doi: 10.1371/journal.pone.0208954. eCollection 2018.
Results Reference
derived
Learn more about this trial
LivRelief Varicose Veins Cream in the Treatment of Varicose Veins
We'll reach out to this number within 24 hrs